Dyne Therapeutics, Inc. 4

Jason P. Rhodes, via Atlas Venture-affiliated funds, sold about 506,695 shares of Dyne Therapeutics, Inc. common stock for roughly $10.7 million in late June 2026 under a Rule 10b5‑1 plan.

On June 26 and June 29, 2026, reporting person Jason P. Rhodes, in his capacity related to various Atlas Venture funds, reported a series of open‑market sales of Dyne Therapeutics, Inc. common stock under a Rule 10b5‑1 trading plan. On June 26, affiliated entities sold 162,954, 81,903, and 64,411 shares at a weighted average price of $21.28 per share, and on June 29 they sold 102,969, 51,756, and 40,702 shares at a weighted average price of $21.14 per share, with actual execution prices ranging from $21.00 to $21.61 and from $21.00 to $21.3247, respectively. In total, approximately 506,695 shares were sold for an aggregate value of about $10.7 million. Following these transactions, the reporting person (through the referenced investment vehicles) reported continuing indirect ownership of 4,476,487, 1,344,719, 975,931, and 7,962 shares of Dyne Therapeutics common stock, with beneficial ownership disclaimed except to the extent of his pecuniary interest in the Atlas Venture funds.

Filing Facts

CIK

1818794

Ticker

DYN

Form

4

Source Type

fda

Accession

0001577014-26-000012

Alert Tier

7